Servando Giráldez

TL;DR: It is determined that both chemotherapeutic agents and proteolytic stress induce CDK1 degradation in human breast cancer MCF7 cells through p62/HDAC6-mediated selective autophagy and is proposed as a potential predictive biomarker of antitumor treatment efficacy.

TL;DR: It is concluded that FBXW7 regulates the response to pac litaxel by targeting MCL1 and PLK1 in breast cancer cells and thus targeting these substrates may be a valuable adjunct for paclitaxel treatment.

TL;DR: For the first time, a single mutation in pttg1 is sufficient to trigger the oncogenic properties of Securin and the finding of this point mutation in patients might be used as an effective strategy for early detection of cancer.

TL;DR: The results support the relevance of GSK-3β and autophagy as two targets for controlling cell cycle progression and proliferative capacity in MCF7, highlighting the co-treatment of breast cancer cells with 3-MA to synergize the effect of the proteasome inhibition.

TL;DR: The finding that treatment with the chemotherapeutic agent doxorubicin in certain cell lines provokes CDK1 degradation and induces apoptosis, whereas in others it inhibits destruction of the protein raises the possibility that different tumor types, depending on their pathogenic spectrum mutations, may display different sensitivity to βTrCP-induced CDK 1 degradation after DNA damage.